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Most of the described structures of podocytes in health and disease have been inferred
from light and electron microscopic studies of rodent models. The variation in filtration
barrier features is measured on micrographs, the aim being statistical significance. This is
the technical campaign waged against kidney disease but this approach can be mislead-
ing.The signaling cascades and connectivity of the podocyte and foot processes (FPs) are
inferred from in vitro studies that at best blurr the reality of the in vivo state.This review will
outline actin signaling connectivity and the key differences in the structural and functional
domains squeezed into the FPs and the relationship of these domains to other parts of
the podocyte. It covers the changes in podocytes during nephropathy concentrating on FP
and finally proposes an alternative interpretation of FP ultrastructure derived from articles
published over the last 60 years.
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INTRODUCTION
The podocyte has an intrinsic part to play in forming and main-
taining the glomerular filtration barrier (GFB), but the relevance
of the various structural components of the GFB in disease is
complex (Figure 1). For instance, the glomerular basement mem-
brane (GBM) not only serves as a barrier to protein in vivo but
also requires the slit diaphragm (SD) to prevent albumin pas-
sage from the capillary lumen into urinary space (1) (Figure 2A).
In addition to SDs, the glycocalyx overlying the endothelial cells
restricts macromolecular passage and ensures that plasma albu-
min is largely excluded from the GFB (2). However, it is mutations
of SD proteins that are strongly linked to the occurrence of pro-
teinuria (3–5), on this basis SDs are assumed to be the weakest
point. The GBM after development is maintained by the podocyte
with dysfunction leading to GBM disruption. However, changes
in the underlying GBM can lead to podocyte dysfunction, which
comes first in disease is unclear.
This review will outline the current view on podocyte structure
focusing on the podocyte foot processes (FPs) with an overview
of associated FP actin signaling and connectivity. Additionally,
regulation and instigation of structural changes associated with
disease states will be outlined. Finally, alternative interpretations
of FP structure and FP changes will be advanced based on the
presence of a subpodocyte space (SPS) (Figure 1).
“NORMAL” PODOCYTE STRUCTURE
Podocyte ultrastructure has been investigated for over half a cen-
tury (6) with the GFB model being developed continuously (7).
The urinary space of the glomerulus has been described as free to
the movement of fluid and small solutes with the GFB being the
single fluid resistance between the blood and urinary spaces (8).
A large number of reviews and articles published in the
scientific literature cover the current description of normal
podocyte structure. Briefly, the cell body has many major processes
(MP) attached to it, primary, then secondary, and some tertiary
MPs branching from the cell body. FPs emerge at right angles
to the MPs and make contact with the underlying GBM (9)
(Figures 1 and 2A).
Foot processes from neighboring podocytes interdigitate with
each other forming a SD with its heavy investment of specific
proteins and structures (10). The importance of podocyte SD
structure is highlighted by exact homologs in insect nephrocyte
SDs employing similar conserved proteins for hemolymph filtra-
tion (11). The highly conserved structure and function between
insects and vertebrates illustrates that nephrocytes and podocytes
are from a very old cell lineage having evolved on filtration barriers
at least since the vertebrate/insect last common ancestor over half
a billion years ago (11).
PODOCYTE CYTOSKELETON
Aside from the longitudinally oriented actin bundles in the central
apical part of FPs, there are three membrane associated domains
(Figure 2A). A sub-plasmalemmal network of cortical branched
actin filaments connects the SD domains (SDD), the basal domain
(BD), and the apical domain (AD) to the actin bundle (12, 13).
At the end of FP adjoining major processes (MPs), actin bundles
connect to MP intermediate filaments and microtubules running
back to the central cell body (14–17) (Figures 2A,B). The complete
FP cytoskeleton is reported as having the components necessary
to oppose the forces of a high pressure distensible glomerular cap-
illary wall (18–20). The FP actin network should not be confused
with MP and cell body actin stress fibers observed in both in vitro
and in vivo podocytes (21).
Podocyte actin filaments organized into stress fibers are in con-
trast to the FP actin network attached to the cell membrane thru
focal adhesions (18). They regulate cell motility and any sustained
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FIGURE 1 | Diagram of a thick section through the cell body of a
podocyte showing foot processes (FPs). FPs arising from the two major
processes (MP) in the diagram are labeled with numbers. Other FPs (cross
hatched) interdigitating with the numbered FPs would have emerged from
the MP of a podocyte neighbor (for further discussion of this figure see the
text). EC, endothelial cell; F, fenestration; GBM, glomerular basement
membrane; MP, major process; L, capillary lumen; US, urinary space; SPS,
subpodocyte space.
FIGURE 2 | (A) The glomerular filtration barrier (GFB) with the disposition of
membrane associated domains in foot processes (FPs). Diagram shows three
FPs with apical domain (AD), basal domain (BD), and slit diaphragm domains
(SDD) outlined. The apical actin bundles are shown, other actin networks
cortical actin (sub-plasmalemmal actin) surrounding the actin bundle are
attached to the various membrane domains. The cortical actin meshwork in
BD and SDD is thicker than AD. ECC, endothelial cell cytoplasm; F,
fenestration; G, glycocalyx. (B) Interdigitating foot process (FP) pattern in
health (left) and after effacement in disease (right). The dashed line in FP
marks the boundary of the actin bundles. MT – microtubules in the major
processes. Actin bundles and cortical actin either reduce to a diffuse band of
actin after effacement or disperse with effacement.
cell body contractions, the structure is similar to that of sarcom-
eres in myocytes with myosin filaments, α-actinin, and regulators
like tropomyosin (22). Tropomyosin is only found in the cell body
of podocytes the equivalent regulator in FP actin networks being
synaptopodin (23).
Small GTPase Rho associated protein kinase ROCK as well
as intracellular calcium levels are the main upstream regula-
tors of myosin activity. Rho and calcium pathways regulate actin
stress fiber dynamics of the cell body (24) as well as the cortical
actin and actin bundles of FP but with different regulators (see
above).
Microtubules and intermediate filaments are not part of FP
structure. Differentiated podocytes in vivo have a mesenchy-
mal intermediate filament pattern with the cell body and MPs
expressing vimentin and desmin (17, 25, 26) and intermediate
filament associated proteins plectin and p250 protein (27, 28).
ENDOCYTOSIS AND EXOCYTOSIS IN FOOT PROCESSES
While endothelial cells and podocytes produce the GBM in devel-
opment, the fully differentiated podocyte assembles and secretes
matrix components into the GBM via the BD. This maintains
the GBM meshwork of collagen IV, laminin, fibronectin, entactin,
agrin, and perlecan (29). Cargos from production sites closer to the
cell body (Golgi apparatus, rough ER) necessarily require trans-
port to FPs via MP microtubules (see below). Endocytotic trans-
membrane proteins exist along the BD membrane (e.g., megalin)
and motor proteins that bind membranes to actin such as myo1e
are recruited in clathrin endocytosis (30). Ultimately, these cargoes
will require transport to the cell body.
MAJOR PROCESS MICROTUBULAR TRANSPORT
The tubulin subunits form a stiff 24 nm-thick tubular structure
along the length of MPs and connect the cell body with FP actin
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networks. The minus-ends of microtubules can be located in
the cell body microtubule organizing center with the plus-end
(fast growing) at the cell periphery, resulting in a neuronal “plus-
end-distal” orientation (31). However, podocyte microtubules are
orientated both ways, allowing transport and elongation in either
direction along MPs (16, 32). Central to distal cargo transport was
shown with movements of virus (33) and also vesicular cargos
were moved from a Golgi apparatus under the control of rab8
(34), another small GTPase.
Evidence of distal to central movements has been seen with
Wilms tumor 1 interacting protein (WT1P) an actin associated
protein (AAP) in FP, which translocates from the SDD to the
nucleus via dynein-microtubule transporters (35) [Stress signaling
initiates loss of WTIP from SDD and suggests a mechanism that
transmits changes in podocyte morphology to the nucleus (35)].
The genes coding for Nephrin (SDD) and podocalyxin (AD) are
dramatically downregulated in mice with decreased levels of WT1
gene expression (36).
The CHO1/MKLP1 (kinesin superfamily motor protein) is
responsible for elongation of minus-end-distal microtubules
in podocyte processes (16). Microtubular associated protein 4
(MAP4) could be another microtubule forming molecule in
podocytes (37) with phosphorylation slowing microtubule assem-
bly along the process.
FOOT PROCESS ACTIN CONNECTIVITY
An ever increasing number of actin regulators adapters and asso-
ciated proteins are being discovered around the cortical actin of
the FP membrane domains and around the apical actin bundle
(see Box 1). The distribution of FP proteins around the different
domains is crucial with different biochemistries setting different
signaling. Some of the major interactions with actin involved in
FP structural change are described below and in Figure 3 [for a
fuller description of the protein complexes see references (13, 38,
39)]. The type of actin interaction by the final signal molecule in
the pathway is also described in Figure 3.
SLIT DIAPHRAGM DOMAIN ACTIN COUPLING IN FPs
In the SD region cortical (sub-plasmalemmal), actin is connected
to the molecules of the SD complex in the membrane (SDD
Figure 2A). ZO-1 (47), catenins (48), CD2AP (49), and podocin
(50) and the like serve as adapter molecules between the slit
membrane molecules nephrin, Neph, and P-cadherin and actin
microfilaments. α-actinin 4 acts as a particularly busy signaling
node (Figure 3A), it is notably abundant in podocyte FPs and
colocalizes with all actin associated with the FPs (51). Arp2/3 also
represents a prominent signaling node. Other classical actin bind-
ing proteins function in different modes – such as the non-muscle
myosin Myo1e, which signals between synaptopodin and actin
and Myo1c interacts directly with nephrin and Neph1 ensuring
insertion in the SDD (38, 39).
APICAL DOMAIN ACTIN COUPLING IN FPs
In the AD (Figure 3C), Syndecans I and IV, podocalyxin GLEPP1,
and podoendin are major contributors to the surface negative
charge on the apical surface (52–54), which is said to repel proteins
and act as a spacer molecule preventing FPs from getting too close
(55). Compared to the SDD, less is known about actin signaling
in the AD. Podocalyxin is joined to the sub-plasmalemmal actin
system via NHERF2 and ezrin (56) podocalyxin complex disrup-
tion results in changes in FP structure (57). Podocalyxin null mice
fail to form FPs (58); even though these changes are in an apical
position away from the SDD and BD.
BASAL DOMAIN ACTIN COUPLING IN FPs
A thicker meshwork of actin is found in the BD facing the GBM and
also the lateral SDD actin network. In the BD of FPs (Figure 3B)
dystroglycan connects actin to agrin in the GBM independently of
α-actinin 4 but a large part of the signaling again centers around
α-actinin 4. Megalin, a transmembrane endocytotic receptor gly-
coprotein links to actin via α-actinin 4 and synaptopodin (59, 60)
and the integrin complex (5) acts through α actinin 4.
Signaling from the GBM to the integrins can regulate actin
dynamics in outside-in signaling (OIS; Figure 3B) but inside-out
signaling (IOS; Figure 3B) also occurs where actin signaling to
the integrin complex alters integrin adhesiveness. Inside-out IOS
signaling can also signal via arp2/3 and vinculin (Figure 3B) (61).
PROMINENT FP SIGNALING NODES
Common signaling components of the three domains are high-
lighted in black throughout Figure 3. These are seen as prominent
nodes and important in the different signaling pathways of the
Box 1 Podocyte actin associated proteins.
The cytoskeletal research impetus has been on the actin cytoskeleton since the only identified mutants in patients have all been based
around this part of the cytoskeleton and no mutations have been identified so far in microtubule or intermediate filament associated genes
(40). Any disruption of microtubule function with colchicine or vinblastine did not appear to alter FP dynamics in the short term (41) (although
the trafficking of cargoes between the cell body and the GBM should result in GBM disruption in the longer term). Any proteinuric kidney
disease that can not be traced to podocytic actin filament disruption is traceable to slit diaphragm change (42).
Podocyte actin research momentum has revealed a huge number of actin associated proteins. A list compiled by Faul showed that 94 actin
associated proteins (AAPs) have been discovered in cultured mammalian podocytes up to 2013. This can be narrowed down to a list of 26
that have mutations associated with human disease or genetic modification resulting in experimental proteinuria (43). How these AAPs
fully interact with the individual podocyte actin domains and networks especially in the FPs remains to be determined.
The list is ever growing: two further podocyte cytoskeletal proteins have been found upregulated in the FPs of puromycin aminonucleoside
nephropathy (PAN) rats and also human disease (44). Survivin (Birc5 gene) colocalizes with synaptopodin and is an actin binder, survivin
knockdown with siRNA rearranges the actin cytoskeleton (45). Another potential is Arc/Arg3.1 (Activity regulated cytoskeleton associated
protein), which acts as a crucial mediator for actin polymerization in other cells. Its possible Arc is associated with podocyte endocytotic
control, weirdly, the gene was upregulated but not the protein in PAN rats (44, 46).
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FIGURE 3 | Foot process membrane and associated domains with
membrane proteins at the top then adapter and effector proteins leading
to actin. Each domain is connected to the underlying cortical actin network
and to the other domains. (N.B. Not all protein interactions are shown) all are
bidirectional biochemical interactions except effector molecule interactions
(arrows). Question marks show uncertainty. White text on black shows
common adapter/effector molecules across the three domains. Most actin
interactions will be with local cortical actin with some potential longer range
actin bundle interactions (AB) Figure adapted from Refs. (13, 38, 39) . (A) Slit
diaphragm domain (SDD). Vertical dashed lines at the top indicate connectivity
across the SD to another FP. Cat, catenin; αAct4-α, actinin4; Cad, cadherin;
Synapto, synaptopodin; BK’Ca – BKCa, splice variant, which binds Nephrin;
Myo1c, myosin 1c; Myo1e, myosin 1e; NMIIA, non-muscle myosin II A;
Actin action: Mena, organizes long actin into bundles inhibits capping.
Cortactin, promotes branching. Arp 2/3, branching and actin nucleation. CapZ,
actin end capping. α Act.4, actin bundler and anchorer. Synaptopodin, actin
bundler. (B) Basal domain (BD). Vertical lines at the top indicate attachment to
GBM components. Dystrog, dystroglycan; Sarcog, sarcoglycan; α3 β1 Int, α3
β1 integrin; αAct4, α actinin 4; Podopl, podoplanin (gp38); OIS, outside-in
signaling (integrins regulate actin dynamics); IOS, inside-out signaling (actin
regulates integrin adhesiveness); NMIIA, non-muscle myosin type IIA.
Actin action: Filamin, binds 2 actins at large angles (to make networks).
Utropin, binds along actin length. NMIIA, motor protein binding 2 actins.
Myo1e, motor protein binding membrane to actin. Nck1/2, actin
polymerization. (C) Apical Domain (AD). Dashed lines at the top indicate
proteoglycan part of the membrane proteins in urinary space. Syndec,
syndecan; αAct4, -α actinin 4; 	, negative charge on proteoglycans
(glycocalyx) Actin action: Ezrin, actin binder. Drebin, actin binder.
three domains. α-actinin 4, Arp2/3, integrin-linked kinase (ILK),
and synaptopodin are highlighted below.
Irrespective of membrane domain α-actinin 4 represents a
prominent signaling node in the three domains but with notice-
ably different connectivity to the cortical actin and actin bundles
of the FP. The network associations in Figure 3 show α-actinin 4
to be closely associated with the cortical actin network and also
active in the actin bundles of FP. Immuno-staining of α-actinin
4 shows location in only the actin bundles in rats (12), whereas
in human podocytes its confined to SDD or BD and not in an
apical actin bundle position (62). The close association with other
proteins in complexes could cloak the α-actinin 4 antigenic site as
it interacts directly with integrins in BD (Figure 3B) and forms
a complex with nephrin and ILK in SDD (63) (Figure 3A). This
highlights caution in interpretation of immuno-staining results.
Arp2/3 is in a separate signaling pathway to α-actinin 4 in
SDD but both interact with vinculin in BD (Figure 3B). Since
Arp2/3 interaction with actin is as an effector then only outside-in
Frontiers in Endocrinology | Diabetes February 2015 | Volume 6 | Article 9 | 4
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signaling (OIS) is possible. Its associations in the AD are still being
defined (Figure 3C).
Integrin-linked kinase (Figures 3A,B) seems to function as
an adaptor that biochemically and functionally connects the BD
and SDD complexes (13, 61). In the SDD, ILK physically inter-
acts with nephrin to form a ternary complex, and α-actinin-4 in
ILK/nephrin complex formation (63) in BD one of its functions is
in relaying signals from integrins to actin (61) (Figure 3B).
Synaptopodin can be described as a scaffolding protein con-
necting the signaling complexes of the SDD and the BD by virtue
of binding to α-actinin and the actin cytoskeleton (13). Small
GTPases like RhoA act as regulators of actin networks and synap-
topodin is involved in the promotion of RhoA-mediated actin
fibril formation at the SDD or BD next to the GBM. However, in
AD podocalyxin can activate RhoA (64).
PODOCYTE CHANGES IN DISEASE
Disruptions in podocyte biochemistry will alter podocyte struc-
ture in disease. The structural changes will be outlined in this next
section and examples given of the underlying signaling.
REDUCTION IN PODOCYTE NUMBER
A reduction in podocyte number per glomerulus is a feature of
FSGS (65, 66). Wharram showed a direct relationship between
reduction in the podocyte population and extent of glomeru-
losclerosis in rats (67), podocyte depletion marks an inability of
the glomerulus to replace podocytes. Detachment of podocytes
due to disruption of cell adhesion proteins in the BD (68) allows
recovery of them as viable cells from urine (69). Apoptosis regu-
lated through cell cycle regulatory proteins (cyclin) and/or caspase
routes can be an early feature in some disease as in type 2 diabetic
kidney disease (70).
Podocyte loss is prevalent in type 2 diabetes (with microal-
buminuria) the lower density of podocytes per glomerulus was
the strongest predictor of renal disease progression (71). Again,
podocyte loss in type 2 diabetic nephropathy scaled with the pro-
gression of the disease (72). However, in type 1 diabetic kidney
disease the frequency of all glomerular cells varied with age in one
study but was not reduced in the diabetic compared to control.
The glomerulus appeared to regulate its architecture to maintain a
constant podocyte density (73, 74). Although the second study did
show a correlation between podocyte loss and proteinuria it was
uncertain whether it was cause or effect of the nephropathy (74).
PODOCYTE DIVISION
How do neighboring podocytes fill in the gaps where podocytes
are lost? Podocytes show no evidence of division in vivo (75), so
how mature podocytes regenerate is unclear. Replacements from
bone marrow have been demonstrated in mice (76, 77) other pos-
sibilities include the parietal cells of the Bowman’s capsule, which
can migrate from the urinary pole to the vascular stalk and there
differentiate into new podocytes (78–80). Using serial multipho-
ton imaging of podocin-confetti mice in a renal fibrosis model the
appearance of a new podocyte was noted within 24 h (81). Thus,
some proportion of the podocyte population or its precursors has
a highly dynamic, motile, and migratory phenotype, which must
involve actin stress fibers.
PODOCYTE HYPERTROPHY
Cell expansion is one possibility for filling the podocyte gaps in
disease, aging rat podocytes have been shown to increase in size
up to twofold. This starts as a non-stressed hypertrophy and pro-
gresses to a severe hypertrophy with a reduction in (functional)
SD proteins, fattening of FPs and increased proteinuria. Loss of
SDs mark a reduction in filtration capacity; however, the resul-
tant GFB still has a podocyte cover. The final stage involves more
podocyte loss and glomerulosclerosis (82). Podocyte hypertrophy
occurs with glomerular capillary hypertension ultimately leading
to progressive glomerulosclerosis (83).
The controllers and regulators of hypertrophy are not com-
pletely resolved. A neuronal protein ubiquitin C-terminal hydro-
lase L1 (UCH-L1) appears to induce podocyte hypertrophy in
Membranous Glomerular Nephritis (MGN) by increasing the total
protein content by promoting cytoplasmic accumulation of pro-
teins such as Cdk inhibitors (p27Kip1) (84). Modification of both
UCH-L1 activity and levels could reduce podocyte hypertrophy
therapeutically in MGN.
The cyclin-dependent kinase inhibitor p27Kip1 is a major reg-
ulator of the podocyte hypertrophic response to hyperglycemia
in vitro (85) and in vivo in a mouse type 2 diabetes model (86) and
levels of p27Kip1 radically increase in experimental nephritis (87).
However, different Cdk inhibitors appear important in podocytes
in vitro, (88) compared to in vivo.
Another regulator of hypertrophy is GLUT4 (an insulin
downstream effector), deficiency in podocytes results in fewer
hypertrophic cells. GLUT4 also protects mice from the devel-
opment of diabetic nephropathy (no proteinuria). There is a
possibility that podocyte hypertrophy concomitant with podocyte
loss may be associated with a protective mechanism avoiding
proteinuria.
Genetic deletion of mTOR complex 1 (mTORC1) in mouse
podocytes induced proteinuria and progressive glomerulosclero-
sis. However, increased mTOR activity accompanied human dia-
betic nephropathy, characterized by early glomerular hypertrophy
and hyperfiltration. These results demonstrate the requirement
for tightly balanced mTOR activity in podocyte homeostasis and
suggest that mTOR inhibition can protect podocytes and prevent
progressive diabetic nephropathy (89).
FP EFFACEMENT
The next response of FPs to disease or abnormal conditions is to
retract toward the MP, any remaining FPs spread out and the nor-
mal interdigitating nature of the FPs gets simplified and smoothed
into an undulation (Figure 2B). In a review on FP effacement, Kriz
et al. pointed out that the process may be an adaptive and protec-
tive response in order to escape cell detachment or to cover bare
areas where cells have been removed (90). This is in contrast to the
old idea of damage and injury.
Effacement can be rapidly induced after only a few minutes
of protamine sulfate, which reduces podocyte surface charge (41)
with no observable change in SDs which apparently remain intact.
α-actinin4 was found in effaced FP basal actin networks consis-
tent with FP effacement being an adaptive change in cell shape,
reinforcing the supportive role of podocytes (91).
www.frontiersin.org February 2015 | Volume 6 | Article 9 | 5
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Neal Podocytes, foot processes, and nephropathic change
ACTIN NETWORK FAILURE
Foot process effacement occurs with the disruption or dispersion
of its actin networks. Rat glomerulopathy effacement occurs with
buildup of a meshwork of intercrossing actin fibers on the FP
BD adjacent to the GBM (91, 92). In contrast, the effacement of
complement-mediated injury (93) or PAN (94) dissociated the
basal actin cytoskeleton from matrix-attached integrins produc-
ing a transient dispersion of actin microfilament structure. How
these structural changes relate or integrate with all the FP actin
domains is unknown (12).
It seems there is a fine biochemical balancing act over activa-
tion or dispersion of actin basal networks, both resulting in FP
effacement. PAN FP effacement was preceded by raised α-actinin
4 expression (91, 95) and transgenic overexpression of α-actinin
4 in mice yields an FSGS phenotype (96). However, mutations of
ACTN4, reducing the levels of normal α-actinin 4, causes a late-
onset FSGS (97) and the mutant crosslinkage with actin causes
loss of nephrin from the SD. In signaling α-actinin-4 is heavily
linked to both SDD (Nephrin, JAM4, p Cadherin; Figure 3A) and
also the BD (via MAGI1 – megalin, α3 β1 integrin; Figure 3B) and
possibly AD (Figure 3C).
The SDD, AD, and BDs of the FPs are physically linked to
the FP cortical actin and central actin bundles, actin is the struc-
tural denominator in podocyte function and dysfunction (5, 98).
Its clear that any interference with the three FP domains (BD,
AD, SDD) and associated cortical actin then affects the FP actin
bundles. These rearrange into either a dense network of short
branching actin filaments (similar to cortical actin meshwork) or
a dispersed network, both arrangements resulting in FP effacement
and proteinuria.
SD LOSS PROMOTING DISEASE
Reduction in cellular levels, mutation or dislocation of SD pro-
teins leads to SD loss or disruption and FP effacement. SD protein
mutations or closely associated FP protein mutations signpost
FSGS. Nephrin, Podocin, CD2AP, PLCε1, and MYO1E (non-
muscle myosin) are autosomal recessive; α-actinin-4, TRPC6, and
INF2 (Inverted Formin 2) are autosomal dominant (99). The
dislocation or loss of only one SD component is necessary and
effacement can occur, in Passive Heymann Nephritis for instance,
it is Nephrin alone that appears to dissociate from SDs (100).
SMALL GTPase REGULATORS OF PODOCYTE ACTIN
The small GTPase group of proteins appears throughout in reg-
ulatory roles involving actin and podocyte shape change. Signals
from the SD to actin and the microtubular system are critical in
maintaining normal position, shape and functioning for the FPs.
Critical regulators are RhoA, Rac1, and Cdc42. A GTPase activat-
ing protein binds CD2AP, which is present in the Nephrin complex
(101), also nephrin can activate Rac 1 through a phosphoinosi-
tide pathway involving another nephrin binder Fyn (102) (not
represented in Figure 3A).
Synaptopodin RhoA interaction seems to be critical for Actin
fibre regulation (103). SD domain TRPC6 mediated calcium influx
activates RhoA and inhibits podocyte motility. Either an increase
or decrease in motility due to RhoA changes lead to FP effacement,
too much or too little disrupts the barrier (104).
RhoA and Rac1 also appear in a similar balanced mechanis-
tic model of podocyte disruption involving a circulating factor
and podocyte protein expression. FSGS and DKD (diabetic kidney
disease) have elevated levels of circulating soluble urokinase plas-
minogen activator receptor (suPAR) but the podocyte expression
of acid sphingomyelinase-like phosphodiesterase 3b (SMPDL3b)
is elevated only in DKD (105).
In FSGS, high SuPAR levels lead to Rac 1 activation and
a migratory phenotype. In DKD, high suPAR levels competi-
tively bind with high SMPDL3b, allowing RhoA activation and
increased apoptosis (Table 1). Healthy podocytes with an absence
of proteinuria mark a balance between the two.
PROBLEMSWITH THE CURRENT STRUCTURAL MODEL
The pathways of actin signaling highlighted here show that the
different domains are complex highly modified evolved structures
that have radically different signaling pathways in closely adja-
cent domains. From above it seems that disruption of often only
a single element of the actin linked pathways in FP in any of the
membrane associated domains leads to effacement. A more recent
interpretation of podocyte structure raises the question of how
basic FP signaling pathways are arranged in FP structure.
The view above simply assumes one type of FP and attached
SD; however, a discovery 60 years ago, which was revisited in
the 1980s and in 2000s challenges this view. The presence of a
subpodocyte space (SPS) was highlighted early on in EM investi-
gations of podocytes. Gautier et al. in 1951 (106) first highlighted
the presence of “lacunaire peri capillaire” (pericapillary lacunae)
under podocyte cell bodies. Elias studied the SPS in the 1980s
(107) but again this was ignored in favor of a simple urinary space
concept.
More recently, the SPS was entirely reconstructed from elec-
tron micrographs and showed that these little urinary spaces were
restrictive to fluid outflow (108–110) (Figure 1). Evidence has
since emerged from two labs, which found SPS in vivo to be a
restrictive space, which trapped 10 kDa macromolecules (111, 112)
but was not restrictive to smaller 450 Da molecules (111). Math-
ematical modeling of the SPS predicted that the fluid resistance
of SPS plus GFB was 2.5 times the “ordinary” uncovered GFB and
exquisitely sensitive to changes in the width of the exit regions
Table 1 |The consequences of circulating levels (+, +++) of suPAR
and podocyte expression levels (+, +++) of SMPDL3b on the
activation (⇑⇑) or inactivation (⇓⇓) of integrins (αVβ3).
FSGS Healthy DKD
SMPDL3b+ SMPDL3b+ SMPDL3b+++
suPAR+++ suPAR+ suPAR+++
αVβ3 ⇑⇑ αVβ3 ⇔ αVβ3 ⇓⇓
RhoA ⇓ Rac1 ⇑ RhoA⇔ Rac1⇔ RhoA ⇑ Rac1⇓
Migration – Apoptosis
Proteinuria – Proteinuria
High levels of SMPDL3b and suPAR competitively bind and inactivate αVβ3. Sub-
sequently a different small GTPase. is activated leading to either a migratory or
apoptotic phenotype. [Tabulated fromYoo et al. (105)].
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leading from the SPS (arrow in Figure 1) (109). This is a problem
for structure-based models predicting fluid permeability without
accounting for an SPS contribution to the barrier (113).
In essence, an SPS is formed by the cell body and some sup-
porting MPs of the podocyte covering up and roofing over more
than 50% of the urinary side of the GFB (108–110). The covered
GFB comprises underlapping MPs and attached FPs sitting on
GBM with the usual fenestrated endothelium on the luminal side
(Figure 1).
FP REDEFINITION
At first glance the GFB underlying the SPS seems to be identical to
the GFB in non-SPS areas with SDs and domains formed between
FPs of neighboring podocytes. However, not all FPs in SPS arise
from MPs because some FPs emerge directly from the cell body
(Figure 1. foot processes 4, 6 and 8). These processes still run par-
allel with other FPs and TEM image reconstruction shows them
to be extended columns supporting the cell body (109).
These major FPs were originally referred to as anchoring
processes (108, 109), here we call them anchoring foot processes
(AFP) for clarity (Figure 4). The original name was applied
when these processes were found to widen under transiently
increased perfusion pressure (approximately 30 s), as if they were
an adjustable anchor for the podocyte cell body on the GBM
(108, 109). The smaller ordinary FPs (OFPs), which have all the
cytoskeletal machinery for shape change did not widen, so AFPs
appeared to be more sensitive to pressure than OFPs.
Looking at AFPs in more detail (Figure 4), there is an SD
domain, a BD but an AD stretching up to the underside of the
podocyte cell body (an SPS “ceiling” domain). If the OFPs and
AFPs are considered separately, some initial questions arise:
CONTRACTILE/CYTOSKELETAL STRUCTURES
1. Do AFPs have OFP type actin bundles, cortical actin, and
membrane associated domains?
2. Do AFPs have cell centric actin stress fibers?
3. Since AFPs are a form of MP do they have microtubules?
4. Do AFPs have a combination of 1, 2, and 3.
SIGNALING NETWORKS
1. What signaling networks and pathways are specific to AFPs
compared to OFPs? Broadly, do the signaling pathways of “FPs”
in Figure 3 occur in AFP?
2. With an increase in perfusion pressure how could the fil-
trate flow (through the SD) or mechanical stretch (of the
podocyte membrane) be transduced allowing the AFP widen-
ing response? (see below)
A POSSIBLE AFP STRETCH/FLOW TRANSDUCTION MECHANISM
Some of the mechanical stretch due to increased perfusion pres-
sure will get exerted at the SD with the components being put
under increased wall stress (hoop or paraxial stress due to the
shape of the underlying capillary). Similarly, any increased filtrate
flow due to increased perfusion pressure will have to pass through
the SDs but exerting an increased radial stress on extracellular SD
components pulling and stretching the SDD membranes. Thus,
either increased wall stress or filtrate flow will both induce stretch
deformations at the SD membranes.
FIGURE 4 |The subpodocyte space (SPS) GFB showing the disposition
of membrane domains in foot processes as in Figure 2. Ordinary foot
processes (OFP) have signaling networks that are well defined. The less
frequent anchoring foot processes (AFP) could have some of the features of
(OFP) but must have some differences based upon their altered response
to increased perfusion pressure. Arrowheads mark the possible
asymmetric slit diaphragm between OFP and AFP. Question marks show
the possibility of differences in all three membrane associated domains.
While in vitro studies show that the identity of the podocyte
mechanosensor remains unclear (114) one possible transduction
pathway could involve stretch sensitive BKCa channels (115),which
are bound to the SD protein complexes (both Nephrin and TRPC6.
Figure 3A). Large conductance calcium activated potassium chan-
nels or BKCa channels could provide a mechanism with TRPC6
to fine-tune Ca2+ influx during normal glomerular function. The
Slo1 subunits of BKCa bind to TRPC6 channels (116) (Figure 3A),
which are expressed in the SD domain, cell body, and through-
out the MP (117). The interactions between BKCa channels and
actin filaments are complex and are likely to have multiple effects
on the overall activity of BKCa channels (118). However, acute
depolymerization of podocyte actin with cytochalasin-D did not
affect BKCa channels (119), suggesting that any stretch activated
response in AFP is not mediated by actin. While actin is thought of
as being the mediator of protrusion and contraction, microtubules
can also fulfill this function (118, 120).
How could differential responses to the same stretch stimulus
arise in adjacent AFP and OFP, which share the same SD? This
variability could be due to BKCa alone since the KCNMA1 gene
that codes for the 4 Slo1 subunits of BKCa has 35 exons, which can
be alternatively spliced at 7 different sites. Thus, BKCa can have
a multiplicity of variants sensitive to various pressure ranges but
crucially, lots of different BKCa splice variants (and heteromers)
can exist in a single cell (121–123). Its not unreasonable to hypoth-
esize high stretch sensitivity splice variants/heteromers in AFP and
low stretch sensitivity splice variants in OFP of the same cell and
also on the other side of an SDD in an adjacent OFP. This could
give the necessary asymmetric response in neighboring FPs. Highly
stretch sensitive BKCa splice variants/heteromers should accord-
ingly be located along AFP borders (SPS) and absent from OFP
ones if this hypothesis works.
Crucially, in the rapid movement of AFP in response to pres-
sure changes integrins can also alter their adhesive characteristics
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in response to cellular events via“inside-out”signaling (61) (IOS in
Figure 3B), allowing them to take up the extra space on the GBM.
The alternative to a local stretch sensor is whole podocyte
stretch sensing, with either BKCa or another mechanosensor. Here,
the differential AFP/OFP mechanisms would rely on different AFP
and OFP effector signaling pathways.
EFFACEMENT, ANCHOR WIDENING AND SPS LOSS
Widening of AFPs and the reduction of SPS under an elevated
stimulus or a modified response could be a mechanism resulting
in the production of effacement. This type of effacement appears
to occur in many published electron micrographs [e.g., Figure 11
in (124)] and begs the question how much podocyte FP efface-
ment is AFP widening in addition to OFP changes. Since SPS is a
partially enclosed region, which accumulates/concentrates 10 kDa
Dextran molecules but not molecules below 450 Da (111, 112) loss
of this space points to a dysfunction in macromolecular transport
by podocytes. Thus, effacement and proteinuria could fit, at least
partly, with AFP widening and SPS loss in disease.
AFP MICROTUBULE TRANSPORT
Since AFPs are MPs (arising direct from cell bodies) its possi-
ble they have microtubules, podocyte MTs are oriented to convey
cargoes both ways to and from the cell body along the MPs (16,
32). AFP associated microtubules might be organized for delivery
to the periphery (i.e., GBM structural proteins from perinuclear
Golgi apparatus) or delivery to the cell body (i.e., cargoes endocy-
tosed from the GBM matrix) or both. The MPs that stretch away
from the podocyte peri-nuclear region carrying many OFPs may
transport in a different fashion to AFPs in SPS. The subtle distinc-
tions between cytoplasmic transport domains in OFPs and AFPs
might not be easy to determine.
CONCLUSION
Clearly, any structural differences, defining characteristics and
functional interactions surrounding AFPs and OFPs and any
effects on SPS will need to be defined under normal in vivo
podocyte conditions before sensible re-assessments of effacement
or podocyte structural change can be made in disease.
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